Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2019 | 1 |
2021 | 2 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer.
Cancers (Basel). 2021 May 28;13(11):2666. doi: 10.3390/cancers13112666.
Cancers (Basel). 2021.
PMID: 34071428
Free PMC article.
Review.
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Isozaki H, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, Langenbucher A, Monroe S, Su W, Cabanos HF, Siddiqui FM, Phan N, Jalili P, Timonina D, Bilton S, Gomez-Caraballo M, Archibald HL, Nangia V, Dionne K, Riley A, Lawlor M, Banwait MK, Cobb RG, Zou L, Dyson NJ, Ott CJ, Benes C, Getz G, Chan CS, Shaw AT, Gainor JF, Lin JJ, Sequist LV, Piotrowska Z, Yeap BY, Engelman JA, Lee JJ, Maruvka YE, Buisson R, Lawrence MS, Hata AN.
Isozaki H, et al. Among authors: cabanos hf.
Nature. 2023 Aug;620(7973):393-401. doi: 10.1038/s41586-023-06303-1. Epub 2023 Jul 5.
Nature. 2023.
PMID: 37407818
Free PMC article.
Item in Clipboard
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F.
Poels KE, et al. Among authors: frisco cabanos h.
Nat Commun. 2021 Jun 17;12(1):3697. doi: 10.1038/s41467-021-23912-4.
Nat Commun. 2021.
PMID: 34140482
Free PMC article.
Clinical Trial.
Item in Clipboard
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, Hafeez N, Bilton SJ, Drier Y, Ji F, Greenberg M, Williams A, Kattermann K, Damon L, Sovath S, Rakiec DP, Korn JM, Ruddy DA, Benes CH, Hammerman PS, Piotrowska Z, Sequist LV, Niederst MJ, Barretina J, Engelman JA, Hata AN.
Raoof S, et al. Among authors: frisco cabanos h.
Oncogene. 2019 Sep;38(37):6399-6413. doi: 10.1038/s41388-019-0887-2. Epub 2019 Jul 19.
Oncogene. 2019.
PMID: 31324888
Free PMC article.
Item in Clipboard
Synthetic molecules that protect cells from anoikis and their use in cell transplantation.
Frisco-Cabanos HL, Watanabe M, Okumura N, Kusamori K, Takemoto N, Takaya J, Sato S, Yamazoe S, Takakura Y, Kinoshita S, Nishikawa M, Koizumi N, Uesugi M.
Frisco-Cabanos HL, et al.
Angew Chem Int Ed Engl. 2014 Oct 13;53(42):11208-13. doi: 10.1002/anie.201405829. Epub 2014 Sep 4.
Angew Chem Int Ed Engl. 2014.
PMID: 25196666
Item in Clipboard
Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F.
Poels KE, et al. Among authors: frisco cabanos h.
Nat Commun. 2022 Sep 23;13(1):5579. doi: 10.1038/s41467-022-33355-0.
Nat Commun. 2022.
PMID: 36151107
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite